Please assess the completion status of the following clinical trial:

Trial Title: ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic, unresectable, or recurrent.~2. Has received at most 1 line of prior non-gemcitabine chemotherapy for:~   * metastatic/unresectable disease.~  * Prior adjuvant gemcitabine, if completed more than 12 months prior to enrollment is not considered as prior line of therapy.~  * Radiosensitizing chemotherapy will not be considered a prior line of therapy.~3. Prior and concurrent therapy4. Measurable disease is required per RECIST criteria 1.1.~5. Age ≥18 years. 6. ECOG performance status 0 or 1 7. Anticipated life expectancy ≥ three months. 8. Central venous access 9. Availability of unstained slides or paraffin block tissue from archived tumor specimen. If not available the subject will undergo a fresh biopsy.~10. Specific pretreatment clinical laboratory parameters that are required within 14 days prior to registration.~11. Subjects must be recovered from any toxicity related to prior anti-neoplastic therapy (to grade \<1).~12. Women of child-bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.~Exclusion Criteria:~1. Receiving any other investigational agents.~2. Subjects with known untreated brain metastases.~3. Subjects receiving hepatic enzyme-inducing antiseizure drugs (EIASD~4. Uncontrolled intercurrent illness~5. Pregnancy~6. Any significant medical condition, laboratory abnormality, or psychiatric illness. 7. Any condition including the presence of laboratory abnormalities.~8. Any condition that confounds the ability to interpret data from the study. 9. Unwillingness or inability to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ-761 (Type: EXPERIMENTAL): A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin.

Based on this trial design, predict the completion outcome and termination type (if applicable).